Managing Type 2 Diabetes: The Impact of Secure Patient-Provider Messaging
Secure messaging presents an opportunity for patients and healthcare providers to collaborate on self-management issues like glycemic control, diet, and exercise.
Type 2 Diabetes
TYPE 2 DIABETES
-
-
In-Hospital Tramadol Use Increases Hypoglycemia Risk in T1D, T2D
Results indicate that blood glucose monitoring should be conducted in hospitalized patients with diabetes. -
Type 2 Diabetes and Antidepressant Drug Use: Is There a Causal Link?
Updated meta-analysis confirms the association between antidepressant drug (AD) use and incident diabetes. Future studies should be aimed at evaluating the effect of single AD on the risk of developing T2D. -
Addressing Psychological Insulin Resistance in Patients With Diabetes
Learn about strategies to reduce a patient’s reluctance to initiate insulin therapy, a phenomenon called psychological insulin resistance.
Video
Latest News
Weight Loss Attenuates Decline in Microvascular Function in Type 2 Diabetes
Weight change, glycemic control, and sulfonylurea use are determinants of either preservation or decline in microvascular function in patients with type 2 diabetes.
Silent Myocardial Infarction Improves CVD Risk Discrimination in Diabetes
Inclusion of silent myocardial infarction in diabetes risk stratification improves risk discrimination over and beyond traditional factors.
Rapid Corneal Nerve Fiber Loss Is a Potential Biomarker for Diabetic Polyneuropathy
Abnormally rapid corneal nerve fiber loss may indicate increased risk for the development and progression of diabetic distal symmetric polyneuropathy.
FDA: Biologic Drugs, Including Insulin, Transitioned to New Regulatory Pathway
Insulin and other biologic drugs, have now transitioned to being regulated as biological products, providing a new pathway for approval of biosimilars and interchangeable versions of these products and introducing competition into the market.
Early Age at Puberty Linked to Increased T2D Risk in Men
For men, early age at puberty is associated with an increased risk for type 2 diabetes.
Addressing Metabolic Syndrome Risk in Shift Workers
Among other strategies, clinicians can suggest changes to lifestyle habits, encourage sleep hygiene, and prescribe pharmacologic interventions to combat risk for metabolic syndrome in shift workers.
Are Glycemic Measures in the Nondiabetic Range Linked to NAFLD?
Increased blood glucose levels, even within the nondiabetic range, are associated with increased risk for nonalcoholic fatty liver disease.
Nonalbuminuric DKD May Have Lower Risk for Mortality, CVD, Renal Decline
Nonalbuminuric diabetic kidney disease is not associated with a worse prognosis than other diabetic kidney disease phenotypes.
Empagliflozin Fast-Tracked for Chronic Kidney Disease Treatment
The FDA has granted Fast Track designation for empagliflozin (Jardiance; Boehringer Ingelheim and Lilly) to reduce the risk of kidney disease progression and cardiovascular (CV) death in adults with chronic kidney disease.
Update for SGLT2 Inhibitors: Temporary Discontinuation Prior to Surgery Recommended
The FDA has approved safety labeling changes for sodium glucose co-transporter-2 (SGLT2) inhibitors. These include canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin.
Want to read more?
Please login or register first to view this content.
Next post in Type 2 Diabetes
